ALDH16A1 Knockout A-549 Polyclonal Cells are a genetically modified cell population derived from the A-549 human lung adenocarcinoma line, generated by CRISPR/Cas9-mediated disruption of the ALDH16A1 gene. This product provides a heterogeneous pool of polyclonal knockout cells, avoiding single?clone artifacts and offering a robust model for functional genomics studies. Unlike monoclonal lines, this polyclonal format captures a spectrum of loss?of?function mutations, enabling researchers to assess ALDH16A1-dependent phenotypes in a more representative cellular context.
The host cell line, A-549, was established from a 58?year?old Caucasian male diagnosed with lung adenocarcinoma. It exhibits adherent epithelial morphology and harbors wild?type KRAS, characteristics that make it one of the most widely used models for non?small cell lung carcinoma. A-549 cells are extensively employed in cancer biology, respiratory toxicology, and drug screening due to their well?characterized growth kinetics and metabolic profile. They recapitulate key features of type II alveolar epithelial cells, including surfactant production and the ability to undergo epithelial?mesenchymal transition, qualities that are invaluable for studying lung cancer progression and therapeutic responses.
ALDH16A1 is a putative member of the aldehyde dehydrogenase superfamily, annotated to participate in the detoxification of reactive aldehydes and in the purine degradation pathway. Although its precise enzymatic activity and regulation remain largely unexplored, ALDH16A1 is thought to oxidize aldehyde intermediates generated from purine catabolism, thereby contributing to uric acid homeostasis and cellular redox balance. In A-549 cells, disruption of ALDH16A1 is expected to impair the metabolism of both endogenous lipid peroxidation?derived aldehydes and exogenous xenobiotic aldehydes, leading to dysregulated uric acid production and increased vulnerability to oxidative stress. The resulting accumulation of reactive aldehyde species may perturb additional metabolic and signaling networks, making this knockout a versatile tool for dissecting aldehyde?mediated cytotoxicity and purine?related pathophysiology.
By eliminating ALDH16A1 in a lung adenocarcinoma background, researchers can investigate how this putative aldehyde dehydrogenase influences tumor cell metabolism, redox adaptation, and stress resilience. This model is particularly relevant for studying the metabolic vulnerabilities of cancer cells, where altered aldehyde detoxification can affect proliferation, survival, and sensitivity to chemotherapy. Furthermore, given genome?wide association studies linking ALDH16A1 variants to serum urate levels and gout, these polyclonal knockout cells provide an experimental platform to explore the cancer?intrinsic consequences of purine metabolism dysregulation and its potential connection to the development of hyperuricemia in cancer patients.
Typical applications include verification of target disruption via Western blotting for ALDH16A1, followed by functional assays such as aldehyde?induced cytotoxicity testing and colony formation to quantify cellular sensitivity. Uric acid quantification and RT?qPCR analysis of key metabolic genes enable detailed assessment of purine metabolism alterations. The model is also suited for measuring oxidative stress markers under basal and challenged conditions, screening xenobiotic toxicity, and studying the role of aldehyde metabolism in drug resistance mechanisms. These cells thus support a broad array of investigations into the intersection of aldehyde detoxification, purine metabolism, and lung cancer biology. For additional technical specifications and assistance, please contact Ascent Research.
